Breast Cancer

Dalpiciclib (Dalp) Plus Endocrine Therapy (ET) as Adjuvant Treatment for HR+/HER2– Early Breast Cancer (BC): The Randomized, Phase 3, DAWNA-A Trial

HER2+, Hormone Receptor Positive (HR+) /

Dalpiciclib + ET significantly improved iDFS in HR+/HER2- early breast cancer: 24-month rates 94.7% vs 90.2% placebo (HR 0.56, p<0.0001).

Dalpiciclib (Dalp) Plus Endocrine Therapy (ET) as Adjuvant Treatment for HR+/HER2– Early Breast Cancer (BC): The Randomized, Phase 3, DAWNA-A Trial Read More »